共 58 条
[1]
Heijl A(2002)Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial Arch Ophthalmol 120 1268-1279
[2]
Leske MC(2000)The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration Am J Ophthalmol 130 429-440
[3]
Bengtsson B(1998)Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures Am J Ophthalmol 126 487-497
[4]
Leske MC(2003)Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma treatment trial Arch Ophthalmol 121 48-56
[5]
Heijl A(2005)Management of glaucoma: focus on pharmacological therapy Drugs Aging 22 1-21
[6]
Hussein M(2004)Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug Exp Eye Res 78 767-776
[7]
Marquis RE(2010)Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension Clin Ophthalmol 4 163-170
[8]
Whitson JT(2004)The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study Ophthalmology 111 1641-1648
[9]
Takagi Y(2005)The Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population Ophthalmology 112 1661-1669
[10]
Nakajima T(2006)Latanoprost nonresponders with open-angle glaucoma in the Japanese population Jpn J Ophthalmol 50 153-157